Novel insulin-based therapies that are currently in development center around convenience and patient adherence, in addition to safety and efficacy. With once-weekly insulins and glucose-sensitive insulins under clinical study, there is hope for expanded treatment options for people with type 2 diabetes who need insulin, many of which take into account patient lifestyles and personal preferences. Join Prof. Simon Heller for a discussion of potential future uses of these technologies.

Visit our website diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn.

Disclosures:

Prof. Simon Heller declares the following:  

Advisory Board: NovoNordisk, Sanofi Aventis, Eli Lilly, Zealand Pharma

Speakers Bureau: NovoNordisk, Astra Zeneca

Consultancy: Zealand Pharma

All conflicts have been mitigated prior to this activity. 

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.

References:

Home PD, Mehta R. Insulin therapy development beyond 100 years. Lancet Diabetes Endocrinol. 2021;9(10):695-707.

Frias JP, Chien J, Zhang Q, et al. Once Weekly Basal Insulin Fc (BIF) is Safe and Efficacious in Patients with Type 2 Diabetes Mellitus (T2DM) Previously Treated With Basal Insulin. J Endocr Soc. 2021;5(s1):A448-A449.

Rosenstock J, Bajaj HS, Janež A, Silver R, Begtrup K, Hansen MV, Jia T, Goldenberg R; NN1436-4383 Investigators. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2020 Nov 26;383(22):2107-2116. doi: 10.1056/NEJMoa2022474. Epub 2020 Sep 22.